netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US

Wanda and Dignity Health launch OncoVerse platform

Feb 29, 2016
-
News, RNS Announcements
RNS Number : 3883Q
NetScientific PLC
29 February 2016

NetScientific plc

Wanda™ partners with leading US Hospital Group Dignity Health™ to launch oncology decision support software platform – OncoVerse™

London, UK – 29 February 2016 – NetScientific plc (“NetScientific” or the “Group”, AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces that its operating subsidiary, Wanda, has signed a collaborative deal with one of the US’s biggest hospital groups, Dignity Health, to launch OncoVerse, a digital health oncology care platform.

OncoVerse is a software platform designed to enable a patient’s care team to collaborate in real-time, allowing clinicians across all disciplines to work together to determine the most effective treatment plan for cancer patients. Dignity Health engaged Wanda to develop the software due to the Company’s proven track record in developing effective platforms that support informed treatment decisions. The software will also help to reduce administrative costs associated with high quality cancer care.

 

Dignity Health is a network of nearly 9,000 physicians and more than 400 care centers, including hospitals and primary care clinics spanning 21 US states. The OncoVerse platform will support Dignity Health’s physicians and healthcare professionals to enable them to make informed decisions on the treatment of cancer patients. It will also enable Dignity Health to expand the geographic reach of its clinical decision-making support system to reach the most rural and remote areas – allowing all patients to benefit from insights previously only shared at large medical centers. 

 

Wanda and Dignity Health are shareholders in Oncoverse LLC, a San Francisco based digital health company, and the creator of the OncoVerseTM software platform. Wanda and Dignity Health will jointly market the Oncoverse platform to other oncology programs across the US later in 2016 to earn revenues through uptake of the platform. The relationship with Dignity Health will also allow for cross-marketing of existing and future Wanda products.

 

Facilitating individualized cancer decision support is becoming increasingly important as cancer therapies advance. Wanda’s core technology aims to improve the efficiency and effectiveness of the management of chronic conditions.

 

Commenting on the news, NetScientific’s Chief Executive Officer, Francois R. Martelet said: “Wanda is the Group’s lead subsidiary in our digital health franchise. The launch of Oncoverse with Dignity Health, and its huge US network, is a significant milestone for the Company and further endorses its core technology. This deal marks the second partnership that Wanda has secured with a leading US healthcare group since the start of 2016 as it continues to develop more platforms to better manage chronic conditions.”

 

 

-ends-

 

Contact Details

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

Tel: +44 (0)20 3514 1800

 

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook / Rosanna Forrest

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

About OncoVerse

San Francisco-based Oncoverse, LLC is a digital health care platform company which enables health care professionals to collaborate on cancer patient care decisions, and to monitor the progress of patient therapies.  OncoverseTM has the potential to transform cancer care delivery by establishing a common platform for all cancer patients to access the best medical expertise, while at the same time providing physicians with an opportunity to present their oncology cases for evidence-based peer collaboration, review, treatment recommendations and second opinions that are available 24/7 from any computer or other web-enabled device.

 

About Dignity Health

Dignity Health, one of the nation’s largest health care systems, is a 21-state network of nearly 9,000 physicians, 59,000 employees, and more than 400 care centers, including hospitals, urgent and occupational care, imaging centers, home health, and primary care clinics. Headquartered in San Francisco, Dignity Health is dedicated to providing compassionate, high-quality and affordable patient-centered care with special attention to the poor and underserved. In FY15, Dignity Health provided $1.7 billion in charitable care and services. For more information, please visit our website at www.dignityhealth.org. You can also follow us on Twitter and Facebook.

 

About Wanda

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific company.  More information about Wanda can be found HERE.

 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment.

For more information, please visit the website at www.netscientific.net.

 

This information is provided by RNS
The company news service from the London Stock Exchange

END

AGRZMGZZMRNGVZZ

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
Vortex co-founder receives US Presidential award
NEXT POST →
NetScientific appoints Prof. Stephen Smith as NED

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
Wanda and Dignity Health launch OncoVerse platform - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT